BioLeap is a drug design company that leverages its proprietary technology platform to identify and optimize lead compounds where other approaches have not been successful.
Unlike random screening approaches, BioLeap’s hypothesis-driven method is particularly effective for designing and improving lead compounds for “difficult” targets where traditional methods have failed. BioLeap’s methodology conceptualizes molecules of practically infinite structural diversity and accurately predicts their relative binding affinity to a target protein. As a result, dramatically fewer compounds need to be synthesized and tested experimentally before achieving pre-clinical milestones. BioLeap creates novel compounds with intellectual property protection, enhances the intellectual property estate around existing compounds, avoids obstructive patents, and generates fast-follower compounds for early market entry.
Company Details
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.bioleap.com
Bioleap, Inc Questions
Bioleap, Inc's website is http://www.bioleap.com
Bioleap, Inc's LinkedIn profile is https://www.linkedin.com/company/bioleap-inc
Bioleap, Inc's industry is
Pharmaceutical Manufacturing
Bioleap, Inc's top competitors are
Alix Avien,
Biolea Naturals - Tr Oils Inc.,
Axiom Bio,
Giz Cosmetics,
Atak Cosmetics,
Lea Kozmetik,
Bioleap,
Keune Haircosmetics Brasil,
Maz Textile Limited,
Sora Cosmetics.
Bioleap, Inc's categories are Pharmaceutical Manufacturing
